Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hepatotoxicity of antituberculosis drugs.

Literature DB >> 8711637

Hepatotoxicity of antituberculosis drugs.

L P Ormerod, C Skinner, J Wales.

Abstract

Entities: Disease

Mesh：

Substances：
Antitubercular Agents

Year: 1996 PMID： 8711637 PMCID： PMC473008 DOI： 10.1136/thx.51.2.111

Source DB: PubMed Journal: Thorax ISSN： 0040-6376 Impact factor: 9.139

× No keyword cloud information.

12 in total

1. Hepatitis cases in isoniazid treated groups and in a control group.

Authors: N Riska
Journal: Bull Int Union Tuberc Date: 1976

2. Fatal hepatotoxicity of anti-tubercular chemotherapy.

Authors: R M Whittington
Journal: Lancet Date: 1991-10-26 Impact factor: 79.321

3. Ocular toxicity from ethambutol.

Authors: K M Citron; G O Thomas
Journal: Thorax Date: 1986-10 Impact factor: 9.139

4. Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales.

Authors: M J Humphries; S P Byfield; J H Darbyshire; P D Davies; A J Nunn; K M Citron; W Fox
Journal: Br J Dis Chest Date: 1984-04

5. Adverse effects of antituberculosis drugs.

Authors: D J Girling
Journal: Drugs Date: 1982 Jan-Feb Impact factor: 9.546

6. Effect of rifampicin and isoniazid on liver function.

Authors: S Lal; S N Singhal; D M Burley; G Crossley
Journal: Br Med J Date: 1972-01-15

7. Hepatotoxicity caused by the combined action of isoniazid and rifampicin.

Authors: D S Askgaard; T Wilcke; M Døssing
Journal: Thorax Date: 1995-02 Impact factor: 9.139

8. Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial.

Authors: D E Snider; M W Long; F S Cross; L S Farer
Journal: Am Rev Respir Dis Date: 1984-04

9. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.

Authors: H Türktaş; M Unsal; N Tülek; O Orüç
Journal: Tuber Lung Dis Date: 1994-02

10. Inter-relations between relapses, drug regimens and compliance with treatment in tuberculosis.

Authors: L P Ormerod; R J Prescott
Journal: Respir Med Date: 1991-05 Impact factor: 3.415

12 in total

1. Current medical treatment for tuberculosis. Resources used for screening could be spent more usefully elsewhere.

Authors: Ruth J Whitfield; Rosemary Khan; Anne Smith; Charlotte F J Rayner
Journal: BMJ Date: 2003-03-08

2. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Authors: Harshad Devarbhavi; Guruprasad Aithal; Sombat Treeprasertsuk; Hajime Takikawa; Yimin Mao; Saggere M Shasthry; Saeed Hamid; Soek Siam Tan; Cyriac Abby Philips; Jacob George; Wasim Jafri; Shiv K Sarin
Journal: Hepatol Int Date: 2021-02-27 Impact factor: 6.047

3. Severe hepatic complications of antituberculous therapy.

Authors: M O Turner; R K Elwood
Journal: Can J Infect Dis Date: 1999-03

Review 4. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors: F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal: Drug Saf Date: 1996-12 Impact factor: 5.606

Review 5. Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors: J G Douglas; M J McLeod
Journal: Clin Pharmacokinet Date: 1999-08 Impact factor: 6.447

Review 6. Hepatotoxic effects of therapies for tuberculosis.

Authors: Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal: Nat Rev Gastroenterol Hepatol Date: 2010-08-31 Impact factor: 46.802

7. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society.

Authors:
Journal: Thorax Date: 1998-07 Impact factor: 9.139